Business Context and Reporting Period
This Form 8-K was filed by Soaring Eagle Acquisition Corp., the special purpose acquisition company that later became associated with Ginkgo Bioworks Holdings, Inc. The report covers events occurring on February 23, 2021, and the closing of the initial public offering on February 26, 2021. It does not present Ginkgo Bioworks operating results.
Key Financial and Capitalization Metrics
- The company completed an IPO of 172.5 million units at $10.00 per unit, generating gross proceeds of $1.725 billion.
- Each unit consisted of one Class A ordinary share and one-fifth of a redeemable warrant. Each whole warrant is exercisable for one Class A ordinary share at $11.50 per share, subject to adjustment.
- The sponsor privately purchased 19.25 million warrants at $1.50 per warrant, generating stated gross proceeds of $28.875 million. No underwriting discounts or commissions were paid on this sale.
- The filing states that $1.725 billion was placed in a U.S.-based trust account, consisting of $1.699125 billion of IPO proceeds, including a $60.375 million deferred underwriting discount, and $25.875 million of private placement warrant proceeds.
- The filing provides no revenue, operating profit, net income, cash flow, margin, or conventional debt metrics because the registrant was a newly formed SPAC.
Material Changes and Transaction Terms
- The IPO and related private placement were completed, and the company entered into underwriting, warrant, trust, registration rights, administrative services, and related agreements.
- Forward purchase agreements were entered into with funds managed by Franklin Advisers and accounts managed by Wellington Management. These agreements contemplated purchases of Class A ordinary shares at $10.00 per share at the time of the initial business combination; the filing text does not provide the committed share amounts.
- The company adopted its Amended and Restated Memorandum and Articles of Association effective February 23, 2021.
- Six independent directors were appointed: Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, and Laurence E. Paul. Audit and Compensation Committees were established.
Guidance, Outlook, Risks, and Unusual Items
- The company was required to use the trust funds to complete an initial business combination or redeem public shares, subject to the charter and applicable law.
- If an initial business combination was not completed within 24 months after the IPO closing, the public shares were generally subject to redemption, subject to applicable law.
- Trust funds were restricted until the earliest of a business combination, certain shareholder-approved charter amendments triggering redemptions, or failure to complete a business combination within the required period. Limited interest could be released for taxes and up to $100,000 for dissolution expenses.
- Private placement warrants had terms differing from public warrants while held by the sponsor or permitted transferees, including non-redemption, transfer restrictions, cashless exercise rights, and registration rights.
- The principal risk was execution of a suitable business combination within the required period; the filing does not provide operating guidance or forecasts.
Investor Verification Points
- Verify the final terms, amount, and closing status of the forward purchase agreements.
- Reconcile the stated $28.875 million gross private placement proceeds with the $25.875 million included in the trust account.
- Review the warrant agreement for dilution, redemption, adjustment, and exercise provisions.
- Confirm the deadline and redemption mechanics applicable to the initial business combination.
- Review the Amended Charter, trust agreement, underwriting agreement, and sponsor arrangements for investor protections and conflicts.